| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
|
N Engl J Med
|
2009
|
11.63
|
|
2
|
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
8.72
|
|
3
|
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy.
|
Nat Biotechnol
|
2005
|
5.80
|
|
4
|
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2010
|
5.62
|
|
5
|
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
|
J Clin Oncol
|
2013
|
5.36
|
|
6
|
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
|
Lancet
|
2007
|
3.85
|
|
7
|
BRAF mutation in metastatic colorectal cancer.
|
N Engl J Med
|
2009
|
3.68
|
|
8
|
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
|
Lancet
|
2008
|
3.62
|
|
9
|
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
|
Clin Cancer Res
|
2002
|
2.86
|
|
10
|
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
|
Clin Cancer Res
|
2011
|
2.52
|
|
11
|
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
|
J Clin Oncol
|
2012
|
2.42
|
|
12
|
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.
|
Cancer Res
|
2003
|
2.32
|
|
13
|
Evidence-based medicine: the time has come to set standards for staging.
|
J Pathol
|
2010
|
2.26
|
|
14
|
Cancer immunotherapy--revisited.
|
Nat Rev Drug Discov
|
2011
|
2.26
|
|
15
|
Histopathological evaluation of resected colorectal cancer liver metastases: what should be done?
|
Histopathology
|
2013
|
2.17
|
|
16
|
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
|
Cancer Res
|
2012
|
2.08
|
|
17
|
Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature.
|
Ann Surg Oncol
|
2011
|
2.06
|
|
18
|
Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET.
|
Radiology
|
2005
|
2.02
|
|
19
|
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.
|
J Clin Invest
|
2011
|
1.91
|
|
20
|
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
|
Eur J Cancer
|
2010
|
1.83
|
|
21
|
Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production.
|
Blood
|
2008
|
1.79
|
|
22
|
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
|
Eur J Cancer
|
2011
|
1.78
|
|
23
|
Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer.
|
Eur J Cancer
|
2012
|
1.73
|
|
24
|
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue.
|
J Cell Mol Med
|
2010
|
1.68
|
|
25
|
Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
|
Clin Ther
|
2010
|
1.67
|
|
26
|
Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
|
Acta Oncol
|
2012
|
1.65
|
|
27
|
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
|
Lancet
|
2005
|
1.60
|
|
28
|
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.
|
Blood
|
2005
|
1.57
|
|
29
|
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
|
Clin Cancer Res
|
2003
|
1.57
|
|
30
|
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.
|
J Clin Oncol
|
2005
|
1.48
|
|
31
|
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
|
Clin Cancer Res
|
2010
|
1.45
|
|
32
|
Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines.
|
Int J Cancer
|
2007
|
1.42
|
|
33
|
Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
|
J Clin Oncol
|
2007
|
1.40
|
|
34
|
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
|
J Clin Oncol
|
2005
|
1.36
|
|
35
|
MicroRNAs in colorectal cancer metastasis.
|
J Pathol
|
2011
|
1.36
|
|
36
|
Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.
|
Cancer Res
|
2013
|
1.35
|
|
37
|
PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.
|
J Immunother
|
2012
|
1.32
|
|
38
|
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
|
Clin Cancer Res
|
2011
|
1.29
|
|
39
|
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.
|
Int J Cancer
|
2013
|
1.26
|
|
40
|
Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.
|
Clin Cancer Res
|
2009
|
1.24
|
|
41
|
Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.20
|
|
42
|
Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging.
|
Proc Natl Acad Sci U S A
|
2011
|
1.19
|
|
43
|
Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
|
Eur J Cancer
|
2010
|
1.17
|
|
44
|
Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.
|
Cancer Immunol Immunother
|
2008
|
1.15
|
|
45
|
Phenotypical and functional characterization of clinical grade dendritic cells.
|
J Immunother
|
2002
|
1.12
|
|
46
|
Development of generic quality indicators for patient-centered cancer care by using a RAND modified Delphi method.
|
Cancer Nurs
|
2011
|
1.11
|
|
47
|
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
|
J Natl Cancer Inst
|
2009
|
1.11
|
|
48
|
Migration of dendritic cell based cancer vaccines: in vivo veritas?
|
Curr Opin Immunol
|
2005
|
1.11
|
|
49
|
Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
|
Clin Cancer Res
|
2012
|
1.11
|
|
50
|
Maximizing dendritic cell migration in cancer immunotherapy.
|
Expert Opin Biol Ther
|
2008
|
1.11
|
|
51
|
Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells.
|
Blood
|
2010
|
1.07
|
|
52
|
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer.
|
PLoS One
|
2013
|
1.04
|
|
53
|
Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
|
Cancer Immunol Immunother
|
2010
|
1.04
|
|
54
|
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.
|
Eur J Cancer
|
2011
|
1.04
|
|
55
|
Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake.
|
J Exp Med
|
2006
|
1.03
|
|
56
|
Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
|
Cancer Res
|
2012
|
1.03
|
|
57
|
Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.
|
Clin Cancer Res
|
2010
|
1.03
|
|
58
|
In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients.
|
Cancer Res
|
2009
|
1.02
|
|
59
|
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
|
Invest New Drugs
|
2005
|
1.01
|
|
60
|
Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
|
Clin Cancer Res
|
2010
|
1.00
|
|
61
|
Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use?
|
Crit Rev Oncol Hematol
|
2012
|
0.99
|
|
62
|
Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.96
|
|
63
|
Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
|
Anticancer Res
|
2010
|
0.96
|
|
64
|
Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival.
|
Ann Surg
|
2014
|
0.95
|
|
65
|
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
|
Eur J Cancer
|
2010
|
0.93
|
|
66
|
The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery.
|
BMC Surg
|
2011
|
0.92
|
|
67
|
Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation.
|
Eur Radiol
|
2012
|
0.92
|
|
68
|
Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.
|
Cancer Immunol Immunother
|
2012
|
0.92
|
|
69
|
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.
|
BMC Cancer
|
2012
|
0.92
|
|
70
|
Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.
|
Ann Surg Oncol
|
2007
|
0.91
|
|
71
|
Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells.
|
Cancer Immunol Immunother
|
2008
|
0.90
|
|
72
|
Development and measurement of guideline-based indicators for patients with non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2011
|
0.90
|
|
73
|
Phenotypical and functional characterization of clinical-grade dendritic cells.
|
Methods Mol Med
|
2005
|
0.89
|
|
74
|
The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer--a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).
|
BMC Cancer
|
2014
|
0.89
|
|
75
|
Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study.
|
Ann Surg Oncol
|
2006
|
0.89
|
|
76
|
Systemic treatment of advanced colorectal carcinoma.
|
Eur J Gastroenterol Hepatol
|
2004
|
0.88
|
|
77
|
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.
|
Expert Rev Anticancer Ther
|
2014
|
0.88
|
|
78
|
In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength.
|
Cancer Res
|
2003
|
0.88
|
|
79
|
Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases.
|
J Magn Reson Imaging
|
2003
|
0.87
|
|
80
|
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
|
Eur J Cancer
|
2008
|
0.87
|
|
81
|
Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands.
|
Acta Oncol
|
2013
|
0.87
|
|
82
|
Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.87
|
|
83
|
Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients.
|
Cancer Immunol Immunother
|
2008
|
0.86
|
|
84
|
Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case.
|
Dis Colon Rectum
|
2008
|
0.86
|
|
85
|
Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate.
|
J Nucl Med
|
2009
|
0.85
|
|
86
|
Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
|
J Clin Oncol
|
2008
|
0.84
|
|
87
|
Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands.
|
Acta Oncol
|
2011
|
0.84
|
|
88
|
Current issues in the targeted therapy of advanced colorectal cancer.
|
Discov Med
|
2010
|
0.83
|
|
89
|
Chemotherapy, which drugs and when.
|
Eur J Cancer
|
2009
|
0.83
|
|
90
|
Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure.
|
Neoplasia
|
2006
|
0.82
|
|
91
|
Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands.
|
Eur J Cancer
|
2012
|
0.82
|
|
92
|
FDG-PET in colorectal cancer.
|
Cancer Imaging
|
2006
|
0.82
|
|
93
|
Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells.
|
J Pathol
|
2004
|
0.81
|
|
94
|
Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.
|
Clin Cancer Res
|
2011
|
0.81
|
|
95
|
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
|
Eur J Cancer
|
2009
|
0.80
|
|
96
|
Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
|
J Clin Oncol
|
2002
|
0.80
|
|
97
|
Activation of human plasmacytoid dendritic cells by TLR9 impairs Fc gammaRII-mediated uptake of immune complexes and presentation by MHC class II.
|
J Immunol
|
2008
|
0.80
|
|
98
|
CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma.
|
Am J Surg Pathol
|
2007
|
0.80
|
|
99
|
Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.
|
J Immunother
|
2016
|
0.79
|
|
100
|
Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.
|
Anticancer Res
|
2011
|
0.79
|
|
101
|
MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
|
Pharmacogenet Genomics
|
2013
|
0.79
|
|
102
|
Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy.
|
Crit Rev Oncol Hematol
|
2005
|
0.79
|
|
103
|
Optimal duration of systemic treatment in metastatic colorectal cancer.
|
Curr Opin Oncol
|
2014
|
0.78
|
|
104
|
Chromosome 20p11 gains are associated with liver-specific metastasis in patients with colorectal cancer.
|
Gut
|
2012
|
0.78
|
|
105
|
A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer.
|
Expert Opin Pharmacother
|
2007
|
0.77
|
|
106
|
Bevacizumab and cancer treatment-related mortality.
|
JAMA
|
2011
|
0.77
|
|
107
|
Encouraging results in older patients receiving chemotherapy: a retrospective analysis of treatment guideline adherence in daily practice.
|
Geriatr Gerontol Int
|
2011
|
0.77
|
|
108
|
Does adjuvant systemic therapy with interferon-alpha for stage II-III melanoma prolong survival?
|
Am J Clin Dermatol
|
2003
|
0.77
|
|
109
|
Real-world cost-effectiveness of oxaliplatin in stage III colon cancer: a synthesis of clinical trial and daily practice evidence.
|
Pharmacoeconomics
|
2013
|
0.77
|
|
110
|
Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.
|
BMC Cancer
|
2014
|
0.77
|
|
111
|
In vivo imaging of therapy-induced anti-cancer immune responses in humans.
|
Cell Mol Life Sci
|
2012
|
0.76
|
|
112
|
The CAIRO and FOCUS studies: which lesson is to be learned?
|
Oncologist
|
2009
|
0.75
|
|
113
|
CAIRO and FOCUS.
|
Lancet
|
2007
|
0.75
|
|
114
|
Drug development in advanced esophagogastric cancer: the art of extrapolation.
|
J Clin Oncol
|
2010
|
0.75
|
|
115
|
5-FU-induced peripheral neuropathy: a rare complication of a well-known drug.
|
Anticancer Res
|
2003
|
0.75
|
|
116
|
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).
|
Cancer Immunol Immunother
|
2013
|
0.75
|
|
117
|
A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
|
Cancer Chemother Pharmacol
|
2002
|
0.75
|